Synaptogenix completes patient enrollment in nih sponsored phase 2b alzheimer's disease trial

- top line results expected during the fourth quarter of 2022 - data safety monitoring board has confirmed no adverse safety issues new york , april 19, 2022 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx) ("the company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it has completed enrolling its target of 100 patients for its ongoing national institutes of health ("nih") sponsored phase 2b clinical trial of bryostatin-1 for patients suffering from advanced and moderately severe alzheimer's disease ("ad"). the company expects to announce topline data from the study during the fourth quarter of 2022.
SNPX Ratings Summary
SNPX Quant Ranking